[1]JournalofMedicinalChemistry,2006,vol.49,#14,p.4392-4408
[2]JournalofMedicinalChemistry,2014,vol.57,#16,p.6949-6964
[1]JournalofMedicinalChemistry,2006,vol.49,#14,p.4392-4408
[1]JournalofMedicinalChemistry,2006,vol.49,#14,p.4392-4408
[1]JournalofMedicinalChemistry,2014,vol.57,#16,p.6949-6964
[1]JournalofMedicinalChemistry,2006,vol.49,p.4392-4408
[1]JournalofMedicinalChemistry,2006,vol.49,p.4392-4408
[1]JournalofMedicinalChemistry,2006,vol.49,p.4392-4408
[2]JournalofMedicinalChemistry,2014,vol.57,p.6949-6964
[1]JournalofMedicinalChemistry,2006,vol.49,p.4392-4408
[1]JournalofMedicinalChemistry,2006,vol.49,p.4392-4408
Title: Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability.
Journal: Toxicology and applied pharmacology 20131201
Title: A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120910
Title: Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer.
Journal: Current drug metabolism 20120901
Title: Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120801
Title: HER2 testing in patients with breast cancer.
Journal: BMJ (Clinical research ed.) 20120611
Title: Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia.
Journal: Investigational new drugs 20120601
Title: Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.
Journal: Journal of clinical pharmacology 20120501
Title: Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer.
Journal: Cancer chemotherapy and pharmacology 20120501
Title: Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control in vivo.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20120301
Title: An isolable acyclic hemiacetal of ansamitocin P-3.
Journal: Magnetic resonance in chemistry : MRC 20120301
Title: Biosynthesis of 3,5-AHBA-derived natural products.
Journal: Natural product reports 20120201
Title: Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.
Journal: Nature biotechnology 20120122
Title: The interplay between mutasynthesis and semisynthesis: generation and evaluation of an ansamitocin library.
Journal: Angewandte Chemie (International ed. in English) 20120116
Title: Combined muta- and semisynthesis: a powerful synthetic hybrid approach to access target specific antitumor agents based on ansamitocin P3.
Journal: Chemistry (Weinheim an der Bergstrasse, Germany) 20120116
Title: Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20120101
Title: Dual carbamoylations on the polyketide and glycosyl moiety by asm21 result in extended ansamitocin biosynthesis.
Journal: Chemistry & biology 20111223
Title: Enhanced production of ansamitocin P-3 by addition of Mg2+ in fermentation of Actinosynnema pretiosum.
Journal: Bioresource technology 20111101
Title: Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review.
Journal: Current opinion in oncology 20111101
Title: Enthusiasm for antibody-drug conjugates.
Journal: Journal of the National Cancer Institute 20111019
Title: Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20111015
Title: SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20111015
Title: A novel pathway for maytansinoid release from thioether linked antibody-drug conjugates (ADCs) under oxidative conditions.
Journal: Chemical communications (Cambridge, England) 20111014
Title: Modeling the effects of drug binding on the dynamic instability of microtubules.
Journal: Physical biology 20111001
Title: Antibody-DM1 conjugates as cancer therapeutics.
Journal: Cancer letters 20110828
Title: N-methylation of the amide bond by methyltransferase asm10 in ansamitocin biosynthesis.
Journal: Chembiochem : a European journal of chemical biology 20110725
Title: Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer.
Journal: Breast cancer research and treatment 20110701
Title: Combinatorial effect of maytansinol and radiation in Drosophila and human cancer cells.
Journal: Disease models & mechanisms 20110701
Title: Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates.
Journal: Journal of medicinal chemistry 20110526
Title: Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism.
Journal: Bioconjugate chemistry 20110420
Title: Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage.
Journal: Bioconjugate chemistry 20110420
Title: The microtubule as a breast cancer target.
Journal: Breast cancer (Tokyo, Japan) 20110401
Title: Mutational biosynthesis of ansamitocin antibiotics: a diversity-oriented approach to exploit biosynthetic flexibility.
Journal: Chembiochem : a European journal of chemical biology 20110307
Title: Megakaryocyte lineage-specific class VI β-tubulin suppresses microtubule dynamics, fragments microtubules, and blocks cell division.
Journal: Cytoskeleton (Hoboken, N.J.) 20110301
Title: Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110201
Title: Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110201
Title: Enhanced production of ansamitocin P-3 by addition of isobutanol in fermentation of Actinosynnema pretiosum.
Journal: Bioresource technology 20110101
Title: Can cancer clinical trials be fixed?
Journal: Nature biotechnology 20110101
Title: Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.
Journal: Breast cancer research : BCR 20110101
Title: World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany.
Journal: mAbs 20110101
Title: [Antibody-drug conjugate--a new age for personalized cancer treatment].
Journal: Chimia 20110101
Title: Cyclization of synthetic seco-proansamitocins to ansamitocin macrolactams by Actinosynnema pretiosum as biocatalyst.
Journal: Chembiochem : a European journal of chemical biology 20101210
Title: Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20101001
Title: Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules.
Journal: Molecular cancer therapeutics 20101001
Title: Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability.
Journal: Molecular cancer therapeutics 20101001
Title: Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1: changes due to modification and conjugation processes.
Journal: Bioconjugate chemistry 20100915
Title: Biological considerations and clinical applications of new HER2-targeted agents.
Journal: Expert review of anticancer therapy 20100901
Title: A new antitumour ansamitocin from Actinosynnema pretiosum.
Journal: Natural product research 20100701
Title: [Current impact of natural products in the discovery of anticancer drugs].
Journal: Annales pharmaceutiques francaises 20100701
Title: Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100601
Title: Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice.
Journal: Journal of pharmacokinetics and pharmacodynamics 20100601
Title: Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer.
Journal: Current opinion in molecular therapeutics 20100601
Title: Preparative isolation and purification of anti-tumor agent ansamitocin P-3 from fermentation broth of Actinosynnema pretiosum using high-performance counter-current chromatography.
Journal: Journal of separation science 20100501
Title: Antibody-maytansinoid conjugates designed to bypass multidrug resistance.
Journal: Cancer research 20100315
Title: Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
Journal: Bioconjugate chemistry 20100101
Title: Tau overexpression inhibits cell apoptosis with the mechanisms involving multiple viability-related factors.
Journal: Journal of Alzheimer's disease : JAD 20100101
Title: [Immunoconjugates, drug-armed antibodies to fight against cancer].
Journal: Medecine sciences : M/S 20091201
Title: Constitutive overexpression of asm2 and asm39 increases AP-3 production in the actinomycete Actinosynnema pretiosum.
Journal: Journal of industrial microbiology & biotechnology 20091101
Title: In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates.
Journal: Molecular cancer therapeutics 20091001
Title: The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090615
Title: Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090615
Title: Formal total synthesis of N-methylmaysenine.
Journal: Organic letters 20090416
Title: Timing of the Delta(10,12)-Delta(11,13) double bond migration during ansamitocin biosynthesis in Actinosynnema pretiosum.
Journal: Journal of the American Chemical Society 20090325
Title: Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection.
Journal: Cancer research 20090315
Title: P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients.
Journal: BMC cancer 20090101
Title: Antibody-maytansinoid conjugates for the treatment of myeloma.
Journal: mAbs 20090101
Title: Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.
Journal: Cancer research 20081115
Title: Hedgehog/GLI-mediated transcriptional inhibitors from Zizyphus cambodiana.
Journal: Bioorganic & medicinal chemistry 20081101
Title: Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study.
Journal: Cancer chemotherapy and pharmacology 20081001
Title: Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma.
Journal: Oral oncology 20080901
Title: Amide N-glycosylation by Asm25, an N-glycosyltransferase of ansamitocins.
Journal: Chemistry & biology 20080825
Title: Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination.
Journal: Bioconjugate chemistry 20080801
Title: Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20080715
Title: Highly active ansamitocin derivatives: mutasynthesis using an AHBA-blocked mutant.
Journal: Chembiochem : a European journal of chemical biology 20080505
Title: Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Journal: Accounts of chemical research 20080101
Title: The ansacarbamitocins: polar ansamitocin derivatives.
Journal: Journal of natural products 20071001
Title: Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate.
Journal: Cancer research 20070701
Title: New amide N-glycosides of ansamitocins identified from Actinosynnema pretiosum.
Journal: Archives of pharmacal research 20070601
Title: Chemoenzymatic approaches toward dechloroansamitocin P-3.
Journal: Organic letters 20070412
Title: Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck.
Journal: International journal of oncology 20070401
Title: An integrative expression vector for Actinosynnema pretiosum.
Journal: BMC biotechnology 20070101
Title: On the biosynthetic origin of methoxymalonyl-acyl carrier protein, the substrate for incorporation of 'glycolate' units into ansamitocin and soraphen A.
Journal: Journal of the American Chemical Society 20061108
Title: A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20061015
Title: Determination of the cryptic stereochemistry of the first PKS chain-extension step in ansamitocin biosynthesis by Actinosynnema pretiosum.
Journal: Chembiochem : a European journal of chemical biology 20060801
Title: Semisynthetic maytansine analogues for the targeted treatment of cancer.
Journal: Journal of medicinal chemistry 20060713
Title: Combinatorial biosynthesis--potential and problems.
Journal: Journal of biotechnology 20060625
Title: Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.
Journal: Cancer research 20060415
Title: Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen.
Journal: Cancer research 20060315
Title: Synthesis of the N-acetylcysteamine thioester of seco-proansamitocin.
Journal: Organic letters 20060105
Title: Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry.
Journal: Protein science : a publication of the Protein Society 20050901
Title: A reversed-phase high-performance liquid chromatography method for analysis of monoclonal antibody-maytansinoid immunoconjugates.
Journal: Analytical biochemistry 20050515
Title: Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy.
Journal: Journal of pharmaceutical sciences 20050401
Title: Metabolism studies of the anti-tumor agent maytansine and its analog ansamitocin P-3 using liquid chromatography/tandem mass spectrometry.
Journal: Journal of mass spectrometry : JMS 20050301
Title: Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry.
Journal: Rapid communications in mass spectrometry : RCM 20050101
Title: Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells.
Journal: Blood 20041201
Title: Technology evaluation: cantuzumab mertansine, ImmunoGen.
Journal: Current opinion in molecular therapeutics 20041201
Title: An API LC/MS/MS quantitation method for ansamitocin P-3 (AP3) and its preclinical pharmacokinetics.
Journal: Journal of pharmaceutical and biomedical analysis 20041119
Title: A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer.
Journal: Cancer research 20041101
Title: Cytotoxic activity of maytanprine isolated from Maytenus diversifolia in human leukemia K562 cells.
Journal: Biological & pharmaceutical bulletin 20040801
Title: In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells.
Journal: Cancer research 20040701
Title: A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20040701
Title: A novel amide N-glycoside of ansamitocins from Actinosynnema pretiosum.
Journal: The Journal of antibiotics 20040501
Title: Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice.
Journal: The Journal of pharmacology and experimental therapeutics 20040301
Title: Recent developments in the maytansinoid antitumor agents.
Journal: Chemical & pharmaceutical bulletin 20040101
Title: The post-polyketide synthase modification steps in the biosynthesis of the antitumor agent ansamitocin by Actinosynnema pretiosum.
Journal: Journal of the American Chemical Society 20031126
Title: Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel-Dreyer chromatography.
Journal: European journal of biochemistry 20030901
Title: Occurrence and non-detectability of maytansinoids in individual plants of the genera Maytenus and Putterlickia.
Journal: Phytochemistry 20030201
Title: Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030115
Title: Identification of asm19 as an acyltransferase attaching the biologically essential ester side chain of ansamitocins using N-desmethyl-4,5-desepoxymaytansinol, not maytansinol, as its substrate.
Journal: Journal of the American Chemical Society 20020612
Title: Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate.
Journal: Cancer research 20020501
Title: Identification of a set of genes involved in the formation of the substrate for the incorporation of the unusual 'glycolate' chain extension unit in ansamitocin biosynthesis.
Journal: Journal of the American Chemical Society 20020424
Title: Perspectives on anti-HER monoclonal antibodies.
Journal: Oncology 20020101
Title: Technology evaluation: C242-DM1, ImmunoGen Inc.
Journal: Current opinion in molecular therapeutics 20010401
Title: Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.
Journal: The Journal of biological chemistry 19901005
Title: Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cells and their vincristine-resistant sublines.
Journal: Cancer research 19860101
